Opportunity: "I just think if you posted with your real name you would not say the things you are saying."
Again, what have I said that is not true? You wont go tit for tat because you have no basis. You just do not like hearing the truth.
As a matter of fact Opportunity, you have been the one that has been making wild statements to shareholders lately. What about all this "rock star" status at the ISOBM? What about all this wait until the ISOBM stuff.
The ISOBM has come and gone and the stock price is still 20 cents.
Next year, the company needs $960,000 cash operating money in addition to other services they can pay for in stock. Add to that the $1,200,000 payments and plus about $180,000 interest to Smithline. A total of about $2.340 million in CASH is needed next year.
Looking at the above, have you ever stopped to think why the stock price is 20 cents? I'll give you a hint. It's not from my posting. It is from the basic fundamentals of the stock.
BTW, what happens to Biocurex will not affect any ability of Inverness to bring RECAF to market. They have the product and can do whatever they want with it. Biocurex could be out of business and they could still sell the product. If RECAF can really help solve some of the diagnostics of cancer, that's great.
